Effect Of Erythropoietin On Chemotherapyinduced Anemia And Chemosensitivity

Objective To investigate the preventional effect of erythropoietin on chemotherapy-induced anemia and the influence of chemosensitivity.Materials and Methods Kun Ming mice were implanted with the S180 sarcoma cells in the left hind groin subcutaneously as an experimental in situ animals model. A dosage of 1000 u / Kg rHuEPO was injected subcutaneously, three times/week, starting 12 days before tumor implantation. 4 days before implantation, anemia was induced using a single dose of carboplatin, 50 mg/Kg injected into the tail vein, resulting in a long-lasting normocytic, normochromic anemia. 5 days after tumor implantation, 60 mg/Kg cyclophosphamide was injected intraperiton to treat the tumor. Tumor growth and blood cell parameters were assessed. 19 days after tumor cells implantation, erythrocyte immune function was assessed by detecting the RBC C3b-RR. Tumors were removed, after routine histological processing, transverse sections were cut and sustained with haematoxylin and eosin. The necrosis areas and the tumor-infiltrating lymphocytic cells (TIL) were observed.Results 1. At the time of CTX chemotherapy, the anemia induced by CBP was prevented by rHuEPO 1000 u/Kg s. c. succesfully. In CBP group, CBP reduced the Hb level to 134. 9g/L from 153. 5 g/L (P<0. 05) . While in EPO+CBP group, Hb was reduced from 165. 9 g/L to 162. 6 g/L (P>0. 05) ?5 days after CTX chemotherapy, the Hb level was 137. 5g/L in EPO+CBP group and 141. 6g/L in control group, both were higher than that in CBP group which was 126. 7g/L (P<0. 05) o 2. After CTX chemotherapy, tumors in all groups became smaller, but tumors in the CBP group regrowed faster than those in thecontrol group and EPO+CBP group. The tumor necrosis areas were bigger and TIL were more in the EPO+CBP group and control group than in the CBP group. 3. The RBC C3b receptor rate (C3b-RR) in the control group and EPO+CBP group was significantly higher than that of the CBP group (P<0. 05) . CBP group:4.3%; EPO+CBP group:11.6%; control group: 12. 0%0Conclusions rHuEPO treatment can prevent anemia or reduce the severity of anemia induced by chemotherapy in mice. It can also improve erythrocyte immune function markedly. The chemotherapy-induced anemia can reduce cytotoxicity of cyclophosphamide in tumors, whereas rHuEPO treatment can restore the sensitivity.